Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the "New Drug Re-examination".

Abbott193 enrolled

Overview

Post marketing surveillance of safety and efficacy for Cholib in Korean patients under the "New Drug Re-examination"

The objective of this surveillance is to identify problems and questions on Cholib® and on the following matters under the condition that the investigational product is in use. 1. Serious adverse event and adverse drug reaction profile * Death or a life-threatening condition * Hospitalization or prolonged hospitalization * Persistent or significant disability/incapacity * Congenital anomaly/birth defect * Other medically significant events 2. Unexpected adverse event/adverse drug reaction profile 3. Known adverse drug reaction profile 4. Non-serious adverse drug reaction profile 5. Other information related to the product safety 6. Efficacy evaluation 7. Study of extended follow-up Surveillance of the safety and efficacy of the subjects who received Cholib® for long-term use at least 24 weeks. 8. Study of special patient Analysis of specific patients such as elderly patients (65 years and above), patients with renal/hepatic disease

Study Type

OBSERVATIONAL

Enrollment

193

Conditions

Dyslipidemias

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Clinical diagnosis of mixed dyslipidaemia who has high triglycerides and low HDL cholesterol level while LDL cholesterol levels are adequately controlled with the corresponding dose of simvastatin monotherapy Exclusion Criteria: * Patients who are hypersensitive (allergic) to peanuts, soybean or any of the ingredients of the medicine * Patients who experienced photoallergy or phototoxic reactions during treatment with fibrates or ketoprofen * Patients who have active hepatic disorder or have serum transaminase increased continuously without identified reason * Patients who have gallbladder disease * Patients who have chronic or acute pancreatitis except acute pancreatitis due to severe hypertriglyceridemia * Patients who have moderately or severely reduced kidney function(estimated glomerular filtration rate \< 60mL/min/1.73m2) * Cholib® administration combined administration with fibrates, statins, danazol, cyclosporine or strong cytochrome P450(CYP)3A4 inhibitor * 145/40mg Cholib® Combined administration with amiodarone, verapamil, amlodipine or diltiazem * Children \<19 years * Pregnant or breast-feeding women * Patients with biliary cirrhosis * Patients who have myopathy and/or previously had rhabdomyolysis or myopathy while taking statins and/or fibrates or had 5 times more creatine phosphokinase than Upper limit of Normal (ULN) while taking statins previously * Patients who have rare hereditary problems with lactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption since this drug contains lactose * Patients who have rare hereditary problems with fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency since this drug contains sucrose * Patients who have LDL Cholesterol ≥130 mg/dL and triglyceride \< 150mg/dL and HDL cholesterol ≥60mg/dL Investigators will refer to the product market authorization (label) for inclusion/exclusion criteria

Locations (10)

Daesung Medical Center

Bucheon-si, South Korea

Isam Clinic

Busan, South Korea

DongRae BongSeng Hospital

Busan, South Korea

Hyundai Medical Clinic

Daegu, South Korea

Outcomes

Primary Outcomes

Incidence of adverse event after Cholib administration in general medical practice

Any adverse events occurred after Cholib® dosing will be recorded. Description of adverse event(s) including type of adverse event(s), onset/end date, severity, action taken, causal relationship to the drug and investigator's view on the adverse event(s) will be captured, whether it is related to the drug or not and until follow up visit more than 1 time during the surveillance period. Lab abnormalities and changes in vital signs are considered to be adverse events only if they result in discontinuation from the study, necessitate therapeutic medical intervention, and/or if the investigator considers them to be adverse events.

Time frame: 24 weeks

Incidence of serious adverse event after Cholib administration in general medical practice

Any serious adverse events occurred after Cholib® dosing will be recorded. Description of serious adverse event(s) including type of serious adverse event(s), onset/end date, severity, action taken, causal relationship to the drug and investigator's view on the serious adverse event(s) will be captured, whether it is related to the drug or not and until follow up visit more than 1 time during the surveillance period. Lab abnormalities and changes in vital signs are considered to be serious adverse events only if they result in discontinuation from the study, necessitate therapeutic medical intervention, and/or if the investigator considers them to be serious adverse events.

Time frame: 24 weeks

Secondary Outcomes

Evaluate four categories based on Serum-Triglyceride, HDL cholesterol, LDL cholesterol, creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine level after Cholib® dosing and test date

All subjects who received Cholib® for at least 12 weeks and follow-up at 24 weeks will be evaluated for efficacy using the four-criteria as follows: Improved, unchanged, exacerbated, not assessable

Time frame: 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.